Bitget App
Trade smarter
MarketsTradeFuturesStocksEarnInstitutionAI & More
ZKsync sets May 4 deprecation date for Lite as project consolidates around Era

ZKsync sets May 4 deprecation date for Lite as project consolidates around Era

The BlockThe Block2026/02/27 11:33
By:The Block

ZKsync (ZK) has set a May 4 deprecation date for ZKsync Lite, widely regarded as Ethereum’s first zero-knowledge rollup, as the project continues focusing on its newer ZK Stack ecosystem. 

Block production on the 2020-era network will cease on that date, permanently freezing its final state to ensure balances cannot be altered post-shutdown, according to a Thursday announcement from the team.

The project described the move as a "planned, orderly sunset for a system that has served its purpose," emphasizing that the deprecation does not affect other ZKsync products such as Era or chains built with the ZK Stack framework. A read-only API will remain available for at least one year following the shutdown to support data access, the team said in the X.

Users have been urged to withdraw assets ahead of the May 4 cutoff for greater convenience, though the team stated that funds not withdrawn by that date will remain fully claimable.

According to L2BEAT, approximately $33.9 million remains canonically bridged to ZKsync Lite, including about $24.9 million in stablecoins, $8.4 million in ETH and derivatives, $313,320 in BTC and derivatives, and $231,130 in other assets.

ZKsync Lite, originally called ZKsync 1.0, supported token transfers, atomic swaps, and NFT minting, but did not include smart contract functionality. Development was halted in March 2023 by Matter Labs, the company behind ZKsync, following the launch of ZKsync Era, a zkEVM designed to support arbitrary smart contracts.

Era represented the "Holy Grail of scaling Ethereum" by enabling developers to port existing applications without sacrificing security.


0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs